In conclusion, we planned a phase II randomized non-comparative study to evaluate neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma, and we expect to improve outcomes in patients with advanced melanoma, with a better insight on the concerned populations through the pathologic examination of tissue samples. The gene discussed is BRAF; the disease is melanoma.